315 related articles for article (PubMed ID: 16312856)
1. Cyclophosphamide, epirubicin, vincristine, and prednisone (CEOP) in the treatment of advanced stage non-Hodgkin's lymphomas with poor histology.
Comella P; Abate G; Fiore M; Di Finizio G; Zarrilli D
J Chemother; 1989 Jul; 1(4 Suppl):1257-8. PubMed ID: 16312856
[No Abstract] [Full Text] [Related]
2. Cyclophosphamide, epirubicin, vincristine and prednisone (CEOP) in the treatment of advanced stage non-Hodgkin's lymphomas with poor histology.
Comella P; Abate G; Fiore M; Di Finizio G; Polverino W; Muto P; Zarrilli D
Haematologica; 1988; 73(6):509-12. PubMed ID: 3148514
[No Abstract] [Full Text] [Related]
3. Cyclophosphamide, epirubicin, vincristine, prednisone, bleomycin, etoposide (CEOP-BE) therapy for intermediate- and high-grade non-Hodgkin's lymphomas.
Mugitani A; Tatsumi Y; Tanaka K; Yasui Y; Inoue T
Anticancer Res; 1999; 19(4C):3393-7. PubMed ID: 10629625
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of effectiveness of adriamycin and epirubicin administered in the CHOP protocol to patients with malignant non-hodgkin's lymphoma].
Rolski J; Koralewski P; Pawlicki M
Wiad Lek; 1993 May; 46(9-10):356-9. PubMed ID: 8236992
[TBL] [Abstract][Full Text] [Related]
5. CEOP/PEB alternating chemotherapy in advanced intermediate and high-grade non-Hodgkin's lymphomas.
Abate G; Tafuto S; Romano A; Gailli E; Corazzelli G
Haematologica; 1992; 77(4):322-5. PubMed ID: 1385277
[TBL] [Abstract][Full Text] [Related]
6. [Biweekly cyclophosphamide, epirubicin, vincristine and prednisolone (CEOP) chemotherapy for the elderly patients with aggressive non-Hodgkin's lymphoma. Tochigi Malignant Lymphoma Study Group for the Elderly Patients].
Izumi T; Muroi K; Hoshino Y; Komatsu N; Ohtsuki T; Yamada M; Tomizuka H; Hatake K; Furusawa S; Miura Y
Gan To Kagaku Ryoho; 1996 May; 23(6):797-800. PubMed ID: 8645033
[No Abstract] [Full Text] [Related]
7. Low-dose epirubicin in combination with cyclophosphamide, vinblastine and prednisone (mini-CEOP) for the treatment of aggressive non-Hodgkin's lymphoma in elderly patients.
Veneri D; Zanetti F; Franchini M; Krampera M; Pizzolo G
Haematologica; 2002 Nov; 87(11):ELT43. PubMed ID: 12414364
[No Abstract] [Full Text] [Related]
8. Comparison of front-line chemotherapy for aggressive non-Hodgkin's lymphoma using the CAP-BOP regimens. The Nebraska Lymphoma Study Group.
Vose JM; Anderson JR; Bierman PJ; Bast M; Weisenburger D; Chan WC; Bishop MR; Armitage JO
Semin Hematol; 1994 Apr; 31(2 Suppl 3):4-8. PubMed ID: 7521065
[No Abstract] [Full Text] [Related]
9. New aspects in the treatment of advanced low-grade non-Hodgkin's lymphomas: prednimustine/mitoxantrone versus cyclophosphamide/vincristine/prednisone followed by interferon alfa versus observation only--a preliminary update of the German Low-Grade Lymphoma Study Group.
Hiddemann W; Unterhalt M; Koch P; Nahler M; Herrmann R
Semin Hematol; 1994 Apr; 31(2 Suppl 3):32-5. PubMed ID: 8073307
[No Abstract] [Full Text] [Related]
10. A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial.
Hertzberg M; Matthews JP; Stone JM; Dubosq MC; Grigg A; Ellis D; Benson W; Browett P; Horvath N; Januszewicz H; Abdi E; Green M; Bonaventura A; Marlton P; Cannell P; Wolf M;
Am J Hematol; 2014 May; 89(5):536-41. PubMed ID: 24481640
[TBL] [Abstract][Full Text] [Related]
11. CHOP versus CNOP (N = mitoxantrone) in non-Hodgkin's lymphoma: an interim report comparing efficacy and toxicity.
Brusamolino E; Bertini M; Guidi S; Vitolo U; Inverardi D; Merante S; Colombo A; Resegotti L; Bernasconi C; Ferrini PR
Haematologica; 1988; 73(3):217-22. PubMed ID: 3139519
[No Abstract] [Full Text] [Related]
12. [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
Huang HQ; Lin XB; Pan ZH; Bu Q; Gao Y; Wang BF; Cai QQ; Xia ZJ; Xu RH; Jiang WQ; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):391-5. PubMed ID: 17892140
[TBL] [Abstract][Full Text] [Related]
13. Full-dose chemotherapy for non-Hodgkin's lymphoma in the elderly. Dutch Hematology-Oncology in Adults Study Group.
Sonneveld P; Hop W; Mulder AH; Michiels JJ; Blijham G; van de Lelie J; Raemakers JW; Nieuwenhuis K; van der Heul C
Semin Hematol; 1994 Apr; 31(2 Suppl 3):9-12. PubMed ID: 8073309
[No Abstract] [Full Text] [Related]
14. Epirubicin (CEOP-Bleo) versus idaurubicin (CIOP-Bleo) in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma: dose escalation studies.
Avilés A; Nambo MJ; Talavera A; Garcia EL; Huerta-Guzman J; Díaz Maqueo JC
Anticancer Drugs; 1997 Nov; 8(10):937-42. PubMed ID: 9436636
[TBL] [Abstract][Full Text] [Related]
15. CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: results of the HE22A99 trial of the Hellenic Cooperative Oncology Group.
Economopoulos T; Psyrri A; Dimopoulos MA; Kalogera-Fountzila A; Pavlidis N; Tsatalas C; Nikolaides C; Mellou S; Xiros N; Fountzilas G
Cancer J; 2007; 13(5):327-34. PubMed ID: 17921732
[TBL] [Abstract][Full Text] [Related]
16. Comparison of CHOP-B vs CEOP-B in 'poor prognosis' non-Hodgkin's lymphomas. A randomized trial.
De Lena M; Maiello E; Lorusso V; Brandi M; Calabrese P; Romito S; Mazzei A; Marzullo F
Med Oncol Tumor Pharmacother; 1989; 6(2):163-9. PubMed ID: 2473364
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of two multi-drug chemotherapy regimens based on mitoxantrone and epirubicin in 44 patients with non-Hodgkin's lymphoma].
Gao HR
Zhonghua Zhong Liu Za Zhi; 1991 Jul; 13(4):287-90. PubMed ID: 1806350
[TBL] [Abstract][Full Text] [Related]
18. Results of three polychemotherapy programs in non-Hodgkin's lymphomas.
Konopka L; Pawelski S
J Chemother; 1989 Jul; 1(4 Suppl):1259-62. PubMed ID: 16312857
[No Abstract] [Full Text] [Related]
19. A randomized phase II study of CEOP with or without semustine as induction chemotherapy in patients with stage IE/IIE extranodal NK/T-cell lymphoma, nasal type in the upper aerodigestive tract.
Ma X; Guo Y; Pang Z; Wang B; Lu H; Gu YJ; Guo X
Radiother Oncol; 2009 Dec; 93(3):492-7. PubMed ID: 19782419
[TBL] [Abstract][Full Text] [Related]
20. Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study.
Sung HJ; Kim SJ; Seo HY; Sul HR; Choi JG; Choi IK; Park KH; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
Br J Haematol; 2006 Jul; 134(1):45-53. PubMed ID: 16803566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
